Drugs / rB/HPIV3
rB/HPIV3
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06026514 | Sep 2023 → Jan 2025 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT03462004 | Mar 2018 → Mar 2019 | Ebola hemorrhagic fever | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00366782 | Mar 2007 → Feb 2011 | Paramyxoviridae infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06546423 Comparator | Jul 2024 → Jun 2025 | parainfluenza virus type 3 infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rB/HPIV3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00366782 ↗ |
| Known as | B/HPIV3/HMPV-PreF-A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06546423 ↗ |
| Known as | B/HPIV3/S-6P | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06026514 ↗ |
| Known as | HPIV3/ΔHNF/EbovZ-GP vaccine | “of HPIV3/ΔHNF/EbovZ-GP vaccine or placebo” NCT03462004 ↗ |
| Modality | Vaccine | “two intranasal, live-attenuated HPIV3 vaccines” PMID 22178099 ↗ Dec 2011 |
| Route | Intranasal | “One vaccination with rB/HPIV3 vaccine (at higher dose) given as nose drops to adults 18 to 49 years of age” NCT00366782 ↗ |